CXCR2 and breast carcinoma: TAM-derived CXCL8 promotes breast cancer stem cell (BCSC) self-renewal and elevates breast cancer metastasis, and the CXCR2 antagonist danirixin inhibits the TAM/CXCL8 regulatory mechanism to eliminate BCSCs [143].